文献速递泌尿男性生殖肿瘤

转移性肾细胞癌一线治疗选择——联合治疗时代的当代治疗范式:综述

Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A Review.
PubMed 文献 · JAMA Oncol · 2022-01-01

本综述回顾了转移性肾细胞癌一线联合治疗的随机3期试验证据,涵盖双免疫检查点阻断及血管内皮生长因子受体联合PD-1阻断等方案。文章讨论了试验间基线特征、统计计划、随访时长、生物标志物及设计差异导致的交叉比较困难,并探讨了预测工具、生物标志物及真实世界数据在患者个体化治疗选择中的作用。结论认为联合方案仍是一线标准治疗,但需深思熟虑的研究设计以准确评估结局并整合新方法。

要点

  • 双免疫检查点阻断和血管内皮生长因子受体联合PD-1阻断均实现了持久疾病控制和总生存期延长。
  • 试验间基线特征、统计计划、随访时长、生物标志物方法和设计差异使交叉比较困难。
  • 联合方案仍将是转移性肾细胞癌一线标准治疗,但需合理研究设计以准确评估结局。

核心结论

  • 联合方案仍将是转移性透明细胞肾细胞癌一线治疗的标准治疗。
  • 需要深思熟虑的研究设计以准确估计结局并将新方法整合入治疗手段。

研究设计与样本

  • 综述,回顾已发表的随机3期试验数据,评估一线联合方案。

主要发现

  • 双免疫检查点阻断和血管内皮生长因子受体联合PD-1阻断均实现了持久疾病控制和总生存期延长。
  • 试验间基线患者特征、统计计划、随访时长、生物标志物衍生方法和试验设计差异使交叉比较困难。

关键数值与推荐

  • 综述汇总了靶向细胞毒性T淋巴细胞抗原4和程序性死亡-1(PD-1)的免疫检查点联合方案,以及靶向血管内皮生长因子受体、PD-1和程序性死亡配体-1的方案。

临床怎么用

  • 原文未据此给出具体推荐。

局限性

  • 试验间基线患者特征、统计计划、随访时长、生物标志物衍生方法和试验设计差异使交叉比较困难。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The treatment landscape of metastatic renal cell carcinoma has evolved rapidly over the last decade. Recent combination approaches heralded by targeting immune checkpoints cytotoxic T-lymphocyte antigen 4 and programmed death-1 (PD-1) have been followed in consecutive years by protocols targeting vascular endothelial growth factor receptor, PD-1, and programmed death ligand-1. The differences in baseline patient characteristics, statistical plans, follow-up length, biomarker-derived approaches, and trial design make cross-trial comparisons difficult. Given the regulatory approval of a number of these regimens, the current available evidence is reviewed herein for combination first-line regimens with published randomized phase 3 trial data. OBSERVATIONS: Combination approaches have transformed outcomes for patients. Durable disease control and prolonged overall survival have been achieved by both doublet immune checkpoint blockade and vascular endothelial growth factor receptor plus PD-1 blockade. Rationale for variations in trial outcome are offered, alongside approaches to navigating patient-empowered treatment selection, focusing on predictive tools, biomarkers, and the role of real-world data. CONCLUSIONS AND RELEVANCE: Advances in the genomic, molecular, and immunologic understanding of metastatic clear cell renal cell carcinoma have lifted the survival curves for this disease markedly in recent years. Combination approaches will remain standard of care in the first-line setting. However, thoughtful study design is needed to accurately estimate outcomes and integrate novel approaches into the treatment armamentarium.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Navani V, Heng DYC. Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A Review. JAMA Oncol. 2022. PMID: 34792538. doi:10.1001/jamaoncol.2021.4337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。